Shots: 

• The company's Rybrevant + CT (carboplatin & pemetrexed) has gained the CHMP’s positive opinion as a 1L therapy for NSCLC associated with activating EGFR exon 20 insertion mutations  

• The opinion was based on the P-III (PAPILLON) trial assessing the safety & efficacy of Rybrevant + CT vs CT in NSCLC patients (n=308) with EGFR exon 20 insertion mutations that showed improved PFS (1EP) & a trend favoring interim OS. 7% TRAEs leading to discontinuation 

• Rybrevant is a bispecific Ab targeting activated & resistant EGFR mutation as well as MET mutations and amplifications 

Ref: Johnson & Johnson  | Image: Johnson & Johnson 

Related Post:- Johnson & Johnson Reports the US FDA’s Approval of Rybrevant Combined with Chemotherapy as a 1L Treatment of NSCLC with EGFR Exon 20 Insertion Mutations

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com